Matches in Wikidata for { <http://www.wikidata.org/entity/Q92576001> ?p ?o ?g. }
Showing items 1 to 42 of
42
with 100 items per page.
- Q92576001 description "article scientifique publié en 2019" @default.
- Q92576001 description "artículu científicu espublizáu n'agostu de 2019" @default.
- Q92576001 description "scientific article published on 01 August 2019" @default.
- Q92576001 description "wetenschappelijk artikel" @default.
- Q92576001 description "наукова стаття, опублікована 1 серпня 2019" @default.
- Q92576001 name "Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis" @default.
- Q92576001 name "Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis" @default.
- Q92576001 type Item @default.
- Q92576001 label "Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis" @default.
- Q92576001 label "Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis" @default.
- Q92576001 prefLabel "Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis" @default.
- Q92576001 prefLabel "Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis" @default.
- Q92576001 P1433 Q92576001-B6C2BAC0-F92E-4D09-8456-46E3E797C4E2 @default.
- Q92576001 P1476 Q92576001-D619839B-9E24-4C56-946A-DECEC20C1765 @default.
- Q92576001 P2093 Q92576001-187CFCAB-8B73-4084-89B7-3BB08A205D90 @default.
- Q92576001 P2093 Q92576001-7A3F7258-6CF0-4704-B997-E578E72685FC @default.
- Q92576001 P2093 Q92576001-FA3EDF6D-6270-4D0C-9B9E-97D6F15994F0 @default.
- Q92576001 P304 Q92576001-1C0138C7-1F16-4278-B64A-FA6628BAD77B @default.
- Q92576001 P31 Q92576001-1C94E01E-F491-45C2-A270-CE934904B742 @default.
- Q92576001 P31 Q92576001-5dc653fc-eb19-4bea-a288-34814a48735f @default.
- Q92576001 P356 Q92576001-9FAAE0B6-7A84-4BAE-9FB1-31CA8024F9C2 @default.
- Q92576001 P433 Q92576001-07292E06-7BE1-4573-AD94-4E269B1F1AFF @default.
- Q92576001 P478 Q92576001-39A084B1-BD38-4BBA-A5B1-BCD3A77131C0 @default.
- Q92576001 P577 Q92576001-B1665C2E-AF54-4876-90E1-772A45506D5E @default.
- Q92576001 P698 Q92576001-F4B4EC88-2659-4F95-B06D-FFD1DD39A0BF @default.
- Q92576001 P921 Q92576001-ABC6CE02-5DBA-466D-AA81-E227A722740A @default.
- Q92576001 P356 S40259-019-00361-6 @default.
- Q92576001 P698 31172372 @default.
- Q92576001 P1433 Q4914612 @default.
- Q92576001 P1476 "Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis" @default.
- Q92576001 P2093 "Joel Reis" @default.
- Q92576001 P2093 "Ron Vender" @default.
- Q92576001 P2093 "Tiago Torres" @default.
- Q92576001 P304 "391-399" @default.
- Q92576001 P31 Q13442814 @default.
- Q92576001 P31 Q7318358 @default.
- Q92576001 P356 "10.1007/S40259-019-00361-6" @default.
- Q92576001 P433 "4" @default.
- Q92576001 P478 "33" @default.
- Q92576001 P577 "2019-08-01T00:00:00Z" @default.
- Q92576001 P698 "31172372" @default.
- Q92576001 P921 Q52849 @default.